Paratek Pharmaceuticals Inc  

(Public, NASDAQ:PRTK)   Watch this stock  
Find more results for NASDAQ:TSPT
+0.32 (1.04%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.99 - 31.77
52 week 16.00 - 45.96
Open 31.53
Vol / Avg. 0.00/94,216.00
Mkt cap 535.83M
P/E     -
Div/yield 8.01
EPS -8.99
Shares 17.56M
Beta 0.55
Inst. own 68%
Aug 10, 2015
Q2 2015 Paratek Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
May 15, 2015
Q1 2015 Paratek Pharmaceuticals Inc Earnings Release
Apr 2, 2015
Q4 2014 Paratek Pharmaceuticals Inc Earnings Release
Mar 20, 2015
Paratek Pharmaceuticals Inc at Biocentury Future Leaders in the Biotech Industry
Mar 2, 2015
Paratek Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -410.76%
Operating margin - -179.59%
EBITD margin - -145.65%
Return on average assets -40.68% -32.06%
Return on average equity -47.37% -
Employees 13 -
CDP Score - -


75 Kneeland St Fl 6
BOSTON, MA 02111-1901
United States - Map
+1-617-2750040 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Paratek Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. The Company began a Phase II study of TO-2061, a low dose of ondansetron adjunctive treatment for patients with obsessive compulsive disorder (OCD), who has not adequately responded to first-line therapy. Intermezzo is formulated as a sublingual tablet containing a bicarbonate-carbonate buffer and is absorbed in both women and men. Intermezzo was studied in two Phase III clinical trials involving more than 370 patients. Ambien and its generic equivalents are available in doses of 5 milligram and 10 milligram. Ambien CR and its generic equivalents are available in doses of 6.25 milligram and 12.5 milligram. It has a primary manufacturing and supply agreement with Patheon, Inc. Patheon to manufacture a supply of Intermezzo for use outside the United States.

Officers and directors

Michael F. Bigham CPA Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Evan Loh M.D. President, Chief Medical Officer, Director
Age: 56
Bio & Compensation  - Reuters
Douglas W. Pagan Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Adam Woodrow Vice President and Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Richard J. Lim Independent Director
Age: 43
Bio & Compensation  - Reuters
Robert Radie Independent Director
Age: 51
Bio & Compensation  - Reuters
Jeffrey Stein Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters